STOCK TITAN
  1. Home
  2. News
  3. AMTI

Applied Molecular Transport Inc - AMTI STOCK NEWS

Welcome to our dedicated news page for Applied Molecular Transport (Ticker: AMTI), a resource for investors and traders seeking the latest updates and insights on Applied Molecular Transport.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Applied Molecular Transport's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Applied Molecular Transport's position in the market.

News
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
Rhea-AI Summary
Cyclo Therapeutics, Inc. (CYTH) and Applied Molecular Transport Inc. (AMTI) have completed a merger, forming a combined company operating as Cyclo Therapeutics with a focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The cash runway has been extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
News
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) reported strong enrollment in its pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”). The company is also on track to close a merger with Applied Molecular Transport, Inc. before the year ends. Additionally, they have taken steps to strengthen their balance sheet and extend their cash position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
earnings
-
News
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Applied Molecular Transport Inc. (AMTI) entered into a definitive merger agreement with Cyclo Therapeutics, focusing on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1). The merger is expected to close by year end 2023, with upcoming milestones including completion of enrollment in pivotal Phase 3 clinical trial in NPC1, reporting top line data and preparation for NDA submission. Financially, the company reported a significant decrease in research and development expenses compared to the same period in 2022, leading to a reduced net loss and cash and cash equivalents of $18.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
earnings
News
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
Rhea-AI Summary
Cyclo Therapeutics and Applied Molecular Transport have entered into a merger agreement, forming Cyclo Therapeutics, Inc. The combined company will focus on advancing Trappsol Cyclo for the treatment of Niemann-Pick Disease Type C1 (NPC1). The closing of the merger is expected to result in approximately $13.7 million in cash for operations until 2H 2024. Upcoming milestones include completing enrollment in a pivotal Phase 3 clinical trial, reporting top-line data, and preparing for NDA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
acquisition
-
News
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Applied Molecular Transport Inc. (AMTI) reported financial results for Q2 2023, with a net loss of $17.3 million compared to $35.9 million in Q2 2022. Cash and cash equivalents as of June 30, 2023, were $22.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.92%
Tags
earnings
-
News
Applied Molecular Transport Reports First Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
earnings
News
Applied Molecular Transport Announces Corporate Leadership Change and Process to Explore Strategic Alternatives
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
management
-
News
Applied Molecular Transport Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.94%
Tags
earnings
-
News
Applied Molecular Transport Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO ’23 Congress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
clinical trial
News
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-57.77%
Tags
clinical trial
Stock AMTI logo
Applied Molecular Transport Inc

Nasdaq:AMTI

AMTI Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

AMTI Stock Data

11.01M
31.86M
21.36%
37.28%
0.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About AMTI

applied molecular transport is developing a pipeline of transformative, targeted oral biological therapeutics that promise to redefine the future of biopharmaceuticals. our deep scientific foundations in mucosal immunology and microbiome-epithelial interfaces have led to the development of powerful technology platforms that are fueling a unique pipeline of first-in-class molecules to treat a wide range of grievous diseases. our oral biopharmaceutical products mimic the biology of microbial and other natural processes that modulate health and disease via mucosal immunology pathways. our targeted therapeutics are directed to the right location to intercept disease at the point of origin of dysregulation. we are advancing a pipeline of targeted oral biological therapeutics to treat autoimmune, inflammation and other diseases, including those associated with cancer, metabolic and hepatologic disorders. our overriding patient-centric goal is to open new biological possibilities based on nov